1

1 Continuous non-invasive hemodynamic monitoring in early onset severe preeclampsia

- 2
- 3 Christina M Ackerman-Banks MD¹
- 4 Jasjit Bhinder MD²
- 5 Maxwell Eder MD³
- 6 Paul Heerdt MD, PhD⁴
- 7 Lissa Sugeng MD, MPH²
- 8 Jeffrey Testani MD, MTR³
- 9 Aymen Alian MD⁴
- 10 Heather Lipkind MD, MS⁵
- 11 Eric Velazquez MD³
- 12 Uma Reddy MD, MPH⁶
- 13 Josephine C Chou MD, MS⁷
- ¹Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX.
- 15 U246381@bcm.edu
- 16 ²Department of Cardiology, Northwell Health, Manhasset, NY
- 17 jbhinder@northwell.edu, Lsugeng@northwell.edu
- 18 ³Department of Cardiology, Yale School of Medicine, New Haven, CT
- 19 maxwell.eder@yale.edu
- ⁴Department of Anesthesiology, Yale School of Medicine, New Haven, CT
- 21 paul.heerdt@yale.edu
- ⁵Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York City, NY
- 23 hlipkind@med.cornell.edu

- ⁶Department of Obstetrics and Gynecology, Columbia University College of Physicians and
- 25 Surgeons, New York City, NY
- 26 Ur2137@cumc.columbia.edu
- 27 ⁷Department of Cardiology, University of Colorado, Aurora, CO
- 28 Word Count: Manuscript: 2909
- 29
- 30 **Corresponding author:**
- 31 Josephine Chou, MD, MS
- 32 Josephine.chou@cuanschutz.edu
- 33 12401 East 17th Ave
- 34 Mailstop B130
- 35 Aurora, CO 80045
- 36
- 37

3

39 Abstract

40 **Objectives:**

- 41 Continuous hemodynamic monitoring offers the opportunity to individualize management in
- 42 severe preeclampsia (PEC). We compared cardiac output (CO) and systemic vascular resistance
- 43 (SVR) measured by bioreactance (NICOM), Clearsite[™] Fingercuff [CS), and 3D-echocardiography

44 (3DE).

45 Study Design:

46 This prospective observational study included 12 pregnant patients with early PEC. CO and SVR

47 were measured simultaneously by NICOM, CS, and 3DE antepartum and 1-2 days postpartum.

48 Using 3DE as the standard, CS and NICOM interchangeability, precision, accuracy, and

- 49 correlation were assessed.
- 50 Results:
- 51 Compared to 3DE-CO, CS-CO was highly correlated (R²=0.70, p=<0.0001) with low percentage
- 52 error (PE 29%) which met criteria for interchangeablity. CS-SVR had strong correlation (R²=0.81,
- 53 p=<0.0001) and low PE (29%). While CS tended to slightly overestimate CO (bias +2.05 +/-1.18
- 54 L/min, limit of agreement (LOA) -0.20-4.31) and underestimate SVR (bias -279 +/-156
- 55 dyes/sec/cm⁵; LOA -580-18.4) these differences were unlikely to be clinically significant. Thus
- 56 CS could be interchangeable with 3DE for CO and SVR. NICOM-CO had only moderate
- 57 correlation with 3DE-CO (R²=0.29, p=0.01) with high PE (52%) above threshold for
- 58 interchangeability. NICOM-CO had low mean bias (-1.2 +/-1.68 L/min) but wide 95% LOA (-4.41
- 59 2.14) suggesting adequate accuracy but low precision in relation to 3DE-CO. NICOM-SVR had
- 60 poor correlation with 3DE-SVR (R²=0.32, p=0.001) with high PE (67%), relatively low mean bias

4

- 61 (238 +/-256), and wide 95% LOA (- 655–1131). NICOM did not meet the criteria for
- 62 interchangeable with 3DE for CO and SVR.
- 63 **Conclusions:**
- 64 Clearsite Fingercuff, but not NICOM, has potential to be clinically useful for CO and SVR
- 65 monitoring in severe preeclampsia.

66 **KEYWORDS**:

- 67 Noninvasive hemodynamic monitoring, severe preeclampsia, cardiac output
- 68 FUNDING:
- 69 The research reported in this publication was supported by the Bahn endowment fund from
- 70 Yale University School of Medicine and the Garite Mini-Sabbatical Grant from the Society for
- 71 Maternal Fetal Medicine.

72 ABBREVIATIONS:¹

¹ PEC=severe preeclampsia CO=cardiac output SVR=systemic vascular resistance **CS=Clearsite Fingercuff** NICOM=non-invasive cardiac monitoring with bioreactance 3DE3=3D-echocardiography PE=percentage error LOA=limit of agreement HDP=hypertensive disorders of pregnancy SBP=systolic blood pressure DBP=diastolic blood pressure MAP=mean arterial pressures SV=stroke volume CVP=central venous pressure LV=left ventricular **EF**=ejection fraction **BP=blood** pressure GLS=global longitudinal strain

5

73 Introduction:

74	Hypertensive disorders of pregnancy (HDP) affect 2-8% of all pregnancies and have been
75	increasing in frequency by up to 25% over the past two decades. ^{1,2} It is a major contributor to
76	maternal and neonatal severe morbidity and mortality with up to 16% of maternal deaths due
77	to HDP. ³ Early onset preeclampsia with severe features (PEC) is new hypertension with
78	evidence of end-organ damage prior to 34 weeks gestation. ⁴ It accounts for 20% of all cases of
79	preeclampsia and is associated with more severe maternal and neonatal disease. ⁵ Early onset
80	PEC also has a distinct hemodynamic profile which manifests as lower cardiac output (CO) and
81	higher systemic vascular resistance (SVR) as compared to both mild PEC and normal
82	pregnancy. ⁶ These abnormal hemodynamics may be predictive of maternal and fetal
83	complications, such as severe hypertension, fetal growth restriction and fetal death. ⁵
84	Continuous hemodynamic monitoring in severe PEC offers the potential to tailor
85	antihypertensive therapy based on hemodynamic profiles, identify disease earlier, and
86	ultimately improve maternal and fetal outomes. ^{6,7} However, hemodynamic assessment in
87	pregnancy has traditionally been difficult. Measuring invasive hemodynamics by Swan-Ganz
88	catheter in pregnancy is neither feasible nor safe. Thus, non-invasive hemodynamics have
89	usually been obtained with echocardiography. Unfortunately, this modality is time-consuming,
90	operator dependent, and only available in discrete time intervals. Newer methods of
91	continuous non-invasive hemodynamics through bioreactance (NICOM, Baxter Medical) or
92	finger cuff pressure (Clearsite [™] [CS], Edwards) have been validated against invasive and non-
93	invasive hemodynamics in other clinical settings, including normal pregnancy. ⁸⁻¹⁰ But neither
94	have been validated in pregnant patients with cardiac disease, including severe PEC. We sought

6

95	o validate CO derived from NICOM (NICOM-CS) and Clearsite (CO-CS) against 3D	
----	--	--

- 96 echocardiography (3DE) derived CO (3DE-CO) in early onset severe PEC.
- 97 Methods:
- 98 <u>Study population:</u>

99	The Yale School of Medicine Human Investigation Committee approved this study. All
100	patients signed an informed consent prior to enrollment. We prospectively enrolled 12
101	pregnant patients admitted with early onset PEC with severe features at a single center from
102	December 2020 to October 2021. PEC with severe features was diagnosed clinically in
103	accordance with diagnostic criteria by the American College of Obstetricians and
104	Gynecologists. ⁴ Inclusion criteria were singleton gestations with PEC with severe features
105	diagnosed between 20 and 34 weeks gestation. Exclusion criteria included chronic hypertension
106	requiring medications, age less than 18 years, and non-English primary language. Chronic
107	hypertension was defined as systolic blood pressure(SBP) \geq 140 mmHg and/or a diastolic blood
108	pressure (DBP) \geq 90 mmHg prior to 20 weeks gestation, as defined by the American College of
109	Obstetricians and Gynecologists. ¹¹

110 <u>ClearSite FingerCuff (Edwards)</u>:

111 The CS Finger Cuff uses the Edwards EV1000 clinical platform which monitors 112 hemodynamic parameters derived from continuous noninvasive measurement of the arterial 113 pressure waveform. The finger cuff has a built in plethysmograph sensor to noninvasively 114 measure the continuous finger arterial blood pressure using an inflatable cuff around the 115 middle phalange of the finger. The brachial arterial pressure waveform is then reconstructed 116 from the measured finger blood pressure pulsations to monitor systolic, diastolic, and mean

7

117	arterial pressures (MAP). Hemodynamic parameters including CO, stroke volume (SV), and
118	heart rate are calculated using a pulse contour method via the ClearSite Algorithm. SVR is
119	calculated after the user manually entered a central venous pressure (CVP) value. These
120	hemodynamic values are reported as 20 second averages on the monitor. The Heart Reference
121	Sensor is used to compensate for hydrostatic pressure differences due to changes in height of
122	the finger relative to the heart, with one end placed at the level of the patient's finger and the
123	other at heart level. ¹²
124	Noninvasive Cardiac Output Monitor (NICOM, Cheetah):
125	The Cheetah NICOM system is a noninvasive cardiac output monitoring device based on
126	bioreactance technology which analyzes relative phase shifts of oscillating currents that occur
127	when current traverses the thoracic cavity. Blood exiting the left ventricle to the aorta creates
128	differences in the sensed current (time delay or phase shift), which NICOM measured to
129	calculate the stroke volume. The sensors also contain an electrocardiogram element which
130	measures heart rate and calculates CO which is reported as a 50 second average. ¹³ The NICOM
131	monitor is attached to a sphygmomanometer cuff which measured blood pressure at 10 minute
132	intervals and allows for calculation of intermittent SVR.
133	3-dimensional transthoracic echocardiography (3DE):
134	Echocardiography-derived CO has been validated against the gold standard swan ganz
135	thermodilution in pregnancy, and has been suggested as a reference for the validation of other
136	CO techniques in pregnancy. ¹⁴ Transthoracic echo was performed by qualified adult
137	sonographers using Phillips iE33. Patients were scanned in the left lateral decubitus position. A

138 three-lead electrocardiogram was used to enable image gating and record heart rate. Left

139	ventricular (LV) ejection fraction (EF) was measured by 3D, which was reconstructed from apical
140	three-, four-, and five-chamber views. CO was calculated directly by the Phillips machine on
141	post-processing. Other measurements obtained included LV global strain and standard 2D and
142	3D measurements. (Table 3) 2D echocardiogram CO has inherent limitations due to angle-
143	dependency of pulse wave Doppler and inaccuracies in left ventricular outflow tract size due to
144	measurement inaccuracies and assumption of uniform morphology. ¹⁵ 3DE eliminates these
145	velocity and geometric assumptions, and also reconstructs CO over 7-14 cardiac cycles as
146	opposed to a single beat which offers a broader view of flow quantification. Therefore, 3DE was
147	chosen as the hemodynamic standard in this study. Kortakoff blood pressure (BP) obtained by a
148	standard sphygmomanometer cuff was used as the reference standard for MAP.
149	Data collection:
150	Patients underwent 60 minute monitoring sessions with NICOM and CS at 2 timepoints:
151	antepartum admission and postpartum day 1 or 2. Simultaneous 3DE was performed at the
152	same time as NICOM and CS monitoring. Sphygmomanometer BP measurements were
153	obtained at 10 min intervals.
154	Statistics and Data Analysis:
155	The primary outcome was CO (L/min). 3DE images for CO processing were acquired over
156	a 10 minute period. Concomitant NICOM-CO and CS-CO during the same 10 minute interval of
157	3DE-CO image acquisition were averaged and used for comparison.
158	The secondary outcome was SVR (dynes*sec*cm ⁻⁵). Using the same 10 minute time
159	period as for the aforementioned CO measurements, concomitant average NICOM-SVR and CS-
160	SVR were compared to 3DE-SVR. CS-SVR was measured directly by the device. For NICOM and

9

161	3DE SVR, the following equation was used: [(MAP – CVP)/CO] x80. For NICOM-SVR, NICOM-
162	MAP and NICOM-CO were used in the equation. For 3DE, 3DE-CO and either NICOM-MAP or CS-
163	MAP were used, and then compared to the same respective modality. CVP was derived from
164	the echocardiographic estimate based on inferior vena cava diameter and respiratory variation.
165	Other hemodynamic parameters including SV (mL), HR (bpm), and (MAP) mmHg) were
166	measured. For hemodynamic trend analysis, NICOM and CS data were averaged for each
167	monitoring day. Echocardiographic measurements included LV EF, LV structure (wall thickness,
168	systolic and diastolic volumes) and LV global longitudinal strain (GLS, %).
169	Data analysis was conducted utilizing IBM SPSS (version 20.0.0.0; 2021). Descriptive
170	statistics were performed for the baseline demographics using frequency or median with
171	interquartile range. With 3DE being considered the reference CO, we assessed for
172	interchangeability with NICOM-CO and CS-CO. Interchangeability was assessed by correlation,
173	accuracy (bias), and precision (95% limits of agreement [LOA]), and percentage error (PE).
174	Correlation was measured by simple linear regression and Pearson's coefficient (R ²), with 2
175	methods being considered interchangeable if $R^2 >= 0.6$. Bias and LOA were calculated with
176	Bland-Altman analysis, and PE defined as 2 times the standard deviation of the bias over the
177	mean. ¹⁶ Two methods may be used interchangeably if the difference in bias is not clinically
178	relevant and PE <=30%. ¹⁷ For example, the average CO in normal pregnancy is 7.9 L/min by
179	invasive monitoring ¹⁸ , so difference of up to 2L/min may be considered small and not clinically
180	significant.
181	Results:

182 <u>Study population:</u>

10

Twelve patients were enrolled. Data from one patient was excluded due to poor 183 184 echocardiographic acoustic windows. Therefore, eleven patients were analyzed and yielded 22 185 data sets. From a maternal perspective, the median age was 33.5 years [29.5-35.3) and the 186 187 median BMI at delivery was 35.5 kg/m² [31.8-40.3]. At the time of enrollment, the median 188 gestational age was 30 weeks [27.8-31.3] with median SBP 172 [167.3-181.8] and median DBP 189 98 [95.8-99.3]. Eight of the 12 patients required acute antihypertensive therapy for severe 190 hypertension. Most commonly, patients received labetalol IV as the preferred therapy for acute 191 severe BP management. From a fetal perspective, the median gestational age at delivery was 192 32 weeks [29.5-34]. Over half of the pregnancies were complicated by fetal growth restriction 193 (66.7%) and nearly all neonates required neonatal intensive care unit admission (91.6%). There 194 was one intrauterine fetal demise and no neonatal demises. (Table 1). Cardiac Output (Figure 1) 195 196 Pearson correlation coefficient comparing CS-CO with 3DE-CO showed strong correlation 197 $(R^2=0.70, p=<0.001)$. Bland Altman analysis comparing CS-CO with 3DE-CO showed a mean bias 198 +/- SD of 2.05 +/- 1.18 L/min, 95% LOA -0.20-4.31, and PE 29% error. Antepartum and 199 postpartum CS calculations were similar. Postpartum CS-CO bias +2.1 +/-1.1 L/min with PE 28% 200 and R^2 =0.72 (p = 0.002) versus antepartum CS-CO bias 1.9 +/- 1.2 L/min with PE 30% and R^2 = 201 0.69 (p=0.002). In contrast, Pearson correlation coefficient comparing NICOM-CO with 3DE-CO showed 202 203 moderate correlation (R²=0.29, p=0.01). Bland Altman analysis comparing NICOM-CO with 3DE-

204 CO showed a mean bias +/- SD of -1.2 +/- 1.68 L/min, 95% LOA -4.41 – 2.14, and PE 52%. High

- 205 PE driven primarily by 2 outliers in the antepartum group. Comparing antepartum to
- 206 postpartum NICOM measurements suggested better correlation and accuracy postpartum.
- 207 Postpartum NICOM-CO bias -0.7 +/-1.74 L/min with PE 29% and R²=0.86 (p <0.001) versus
- 208 antepartum NICOM-CO bias 1.18 + 4.18 L/min with PE 69% and R²= 0.27 (p=0.12).
- 209 <u>Systemic Vascular Resistance (Figure 2)</u>
- 210 Pearson co-efficient comparing CS-SVR to 3DE-SVR showed strong correlation (R²=0.81,
- 211 p=<0.0001). Bland Altman comparing CS-SVR to 3DE-SVR showed a bias +/- SD -279 +/- 156
- 212 dyes/sec/cm⁵, 95% LOA -580 18,4, and PE 28%.
- 213 Pearson co-efficient comparing NICOM-SVR to 3DE-SVR showed poorer correlation (R²=0.32,
- p=0.001). Bland-Altman comparing NICOM-SVR and 3DE-SVR CO showed a bias +/-SD 238 +/-
- 215 256, 95% LOA 655 1131, and PE 67%.
- 216 Mean Arterial Pressure
- 217 Pearson correlation coefficient comparing CS-MAP with sphygmomanometer BP showed strong
- correlation (R²=0.73, p=<0.01). Bland Altman analysis comparing CS-MAP with
- sphygmomanometer BP showed a mean bias +/- SD of 2.33 +/- 9.9 mmHg, 95% LOA -17 21.7,
- and PE 19%.
- 221 <u>Hemodynamic Trends (Table 2)</u>
- 222 There was no significant difference between antepartum and postpartum CO, SVR, and MAP
- according to both modalities. However patient population was small, and these trends were not
- 224 statistically significant.
- 225 <u>Echocardiographic Parameters (Table 3)</u>

226	Between the antepartum and postpartum periods, there were no significant changes in left
227	ventricular function or structure. The average EF was 63% antepartum and 62% postpartum.
228	GLS was slightly lower postpartum (21.5% vs 20.2%), however this difference was not
229	statistically significant, and both values were within normal limits.
230	Discussion:
231	We performed a prospective observational study in 12 patients with early onset severe
232	preeclampsia to evaluate CO derived from the Clearsite Fingercuff and NICOM against 3DE-CO.
233	To our knowledge, this is the first study evaluating both of these methods in the preeclampsia
234	population. We found that CS-CO showed strong correlation and sufficiently low PE to be
235	considered interchangeable with 3DE measurements. CS tended to over-estimate CO as
236	compared to 3DE (bias +2.05 L/min). As previously described, two measurement methods may
237	be considered interchangeably if the difference in bias is not clinically relevant and PE $<=30\%$. ¹⁷
238	Given that the average CO in normal pregnancy is 7.9 L/min by invasive monitoring ¹⁸ , our
239	observed difference of approximately 2L/min may be considered small and not clinically
240	significant. Furthermore CS-CO demonstrated strong correlation with 3DE-CO, with the
241	difference between CS and 3DE rising as CO rises. This suggests that if needed for concordance,
242	there is a systematic, linear offset for CS-CO that can be compensated for by applying a
243	regression equation. CS-MAP correlated strongly and could be considered interchangeable with
244	sphygmomanometer BP, which is consistent to prior studies. ¹⁹ CS-SVR also had strong
245	correlation and sufficiently low PE to be considered interchangeable with 3DE measurements.
246	CS tended to under-estimate SVR as compared to 3DE (mean bias -293 dyes/sec/cm 5), but may
247	be considered small compared with the average pregnancy SVR of 980 dynes/sec/cm⁵.

Therefore while CS tends to slightly overestimate CO and underestimate SVR, these differences

249	were small and not clinically significant. Therefore CS could be considered clinically
250	interchangeable with 3DE for CO and SVR. These findings support Clearsite Fingercuff as a
251	potential clinically useful modality for real-time hemodynamic monitoring in severe
252	preeclampsia.
253	Our results differ from a prior study evaluating CS from 2DE TTE in 3 rd trimester
254	pregnancy which showed an unacceptable agreement for CO measurements between these 2
255	modalities. ²⁰ This may be due to our use of 3DE as the reference standard, as opposed to 2DE.
256	However given these contrasting findings, further studies to clarify the validity of CS in the
257	preeclamptic population are warranted.
258	In contrast, NICOM- CO measurements showed only moderate correlation with 3DE-CO.
259	Additionally, calculated PE was too high to meet criteria for interchangeability. ¹⁶ NICOM-CO
260	tended to under-estimate CO as compared to 3DE. While the lower bias suggests that NICOM-
261	CO may be more accurate compared to CS-CO, the wider LOA suggests it is less precise.
262	Similarly, NICOM-SVR had poor correlation and a calculated PE too high to meet criteria for
263	interchangeability. These findings suggest that NICOM would not be clinically useful for
264	continuous hemodynamic monitoring in severe preeclampsia. Prior studies showed that NICOM
265	CO assessment had acceptable correlation with echocardiogram-derived CO in normal
266	pregnancy. ^{10,21} Differences in our results could be explained by differences in body habitus –
267	NICOM accuracy is limited by obesity, and the majority of our patients had BMI >30 kg/m ² at
268	the time of delivery. This is in contrast to prior study cohorts with an average third trimester
269	BMI of 26 kg/m ² . ²¹ The different hemodynamic profile in severe preeclampsia (lower CO and

14

higher SVR as compared to normal pregnancy) may also be a factor, as Doherty et al found
lower NICOM accuracy at lower CO.¹⁰

272 Interestingly, when comparing antepartum and postpartum NICOM-CO measurements 273 against 3DE, NICOM demonstrated better accuracy and precision and lower PE in the 274 postpartum period. It is also notable that the most outlying data points for NICOM-CO occurred 275 during antepartum measurements. Thus NICOM inaccuracies in the antepartum period may be 276 driven primarily by the gravid uterus elevating the diaphragm and altering thoracic anatomy. A 277 prior study showed that upper abdominal surgical procedures reduced NICOM reliability 278 compared to echocardiogram. Postulated reasons included upper diaphragm displacement 279 which alter electrical flux through the thorax and changes in shape and position of the heart. 280 Similar physiologic changes occur during pregnancy, which would affect NICOM accuracy antepartum but resolve postpartum. Our findings suggest that while NICOM could be used for 281 282 hemodynamic monitoring in the postpartum period, it cannot be considered clinically useful in 283 the pregnant population at this time.

284 Our study showed no significant differences between antepartum and postpartum CO, 285 SVR, and MAP for both the NICOM and CS modalities. These trends did not reach statistical 286 significance due to the small study population; however, they are still hypothesis generating. 287 After normal pregnancy, CO drops and SVR rises in the immediate postpartum period.²² The 288 lack of change in CO and SVR in our severe preeclampsia population may be due to the effects 289 of antihypertensive treatment. Since the majority of our patients received labetalol, this raises 290 the possibility that CO may be higher in the postpartum preeclampsia population as compared 291 to antepartum. Further studies are needed to clarify the hemodynamic effects of

15

antihypertensives in severe preeclampsia, and if adjusting medical treatment based on
hemodynamics can improve blood pressure control, hemodynamics, and maternal/fetal clinical
outcomes.

295 There are several limitations to our study because it was performed at a single center 296 with small sample size limited by disease selection and funding. First, meaningful concordance 297 analysis was not feasible due to small sample size and limitation of one hemodynamic set per 298 3DE study. However correlation analysis suggests that CS-CO bias can be corrected with a 299 regression equation, though this would not be feasible with NICOM-CO. Second, outlying data 300 points, such as those seen in NICOM-CO, may have a more prominent effect on 301 interchangeability analysis due to the small sample size. Larger studies in a similar patient 302 population would help clarify the extent to which NICOM-CO accuracy is affected by anatomic 303 limitations as described above, particularly in the antepartum period. Third, we utilized a 304 reference method of 3DE for hemodynamics because invasive hemodynamics with a swan-ganz 305 catheter was not feasible or safe in a pregnant population. Best efforts were made to ensure 306 good acoustic windows and accurate hemodynamic values, but there still may be some 307 discrepancy from invasive hemodynamic values. Lastly our study population represents a 308 subset of the pregnant population, Therefore, applicability to other HDP populations, such as 309 preeclampsia without severe features and gestational hypertension, requires further 310 confirmation.

In summary, CS-CO and SVR could be considered be interchangeable with 3DE-CO and
 3DE-SVR, respectively. CS tends to slightly overestimate CO and underestimate SVR, these
 differences were small and unlikely clinically relevant. Therefore, CS could be considered

314	clinically interchangeable with 3DE for CO and SVR. In contrast, NICOM-CO and NICOM-SVR
315	showed poorer correlation with less precision, and could not be considered interchangeable
316	with 3DE-CO and 3DE-SVR, particularly in the antepartum period. These findings suggest that
317	the CS fingercuff, but not NICOM, has potential to be clinically useful for real-time CO and SVR
318	monitoring in patients with preeclampsia with severe features. Further studies in a larger
319	sample size and in other hypertensive disorders of pregnancy are needed to confirm our
320	findings and inform applications to clinical care.

- 322 Figures:
- 323 Figure 1: Cardiac Output: Correlation and Bland-Altman
- 324 Figure 1a: [CS CO] vs [3DE CO]





327 328

Figure 2: Systemic Vascular Resistance: Correlation and Bland-Altman

329 Figure 2a: [CS SVR] vs [3DE SVR]



Figure 2b: [NICOM SVR] vs [3DE SVR]



19

337 **Tables:**

338

339 Table 1: Baseline characteristics of study population

	N=12 (%)
Maternal Age (y), median [IQR]	33.5 [29.5-35.3]
Ethnicity	
Hispanic	2 (16.6)
Non-hispanic	10 (83.3)
Race	
White	8 (66.7)
Black	1 (8.3)
Asian	1 (8.3)
Other	2 (16.6)
Insurance	
Private	9 (75)
Medicaid	3 (25)
Nulliparity	5 (41.6)
BMI at delivery (kg/m ²), median [IQR]	35.5 [31.8-40.3]
<25	1 (8.3)
25-29.9	1 (8.3)
30 to 34.9	3 (25)
35-39.9	3 (25)
>40	4 (33.3)
Pre-pregnancy BMI (kg/m ²), median [IQR]	31 [27.8-34.5]
<25	1 (8.3)
25-29.9	4 (33.3)
30 to 34.9	4 (33.3)
35-39.9	2 (16.6)
>40	1 (8.3)
Gestational diabetes	1 (8.3)
Smoking	2 (16.6)
Chronic hypertension not requiring medications	1 (8.3)
Gestational age at enrollment (weeks), median[IQR]	30 [27.8-31.3]
Systolic blood pressure at enrollment (mmHg), median [IQR]	172 [167.3-181.8]
Diastolic blood pressure at enrollment (mmHg), median [IQR]	98 [95.8-99.3]
Antihypertensive management for severe hypertension	
Labetalol IV	6 (50)
Nifedipine IR	1 (8.3)
Hydralazine IV	1 (8.3)
HELLP syndrome	3 (25)
Laboratory values upon hospital admission	

0.93 [0.3-4.6]
32.5 [21.3-42.3]
21 [13-25.5]
250 [174-272.8]
0.64 [0.6-0.7]
1 (8.3)
10 (83.3)
1 (8.3)
32 [29.5-34]
8 (66.7)
11 (91.6)
0
1 (8.3)
1300 [1110-1915]
6 [4-7.3]
9 [8-9]
4 (33.3)
1 (8.3)
4 (33.3)
3 (25)

341

342

343 Table 2: Average hemodynamics ante- and post-partum by modality: CS and NICOM

344 Table 2a: CS ante- and post-partum average hemodynamics

CS	Antepartum	Postpartum	P value
CO L/min	8.8	8.4	0.50
SVR dynes*sec*cm-5	1017	1032	0.90
MAP	107	105	0.70
HR	81	76	
SV mL	108	111	

345

346 Table 2b: NICOM ante- and post-partum average hemodynamics

NICOM	Antepartum	Postpartum	P value
CO (L/min)	5.4	5.7	0.61
SVR (dynes*sec*cm-5)	1562	1344	0.37
MAP	105	102	0.46
HR bpm	81	78	
SV mL	67	73	

347

349

350 Table 3: Echocardiographic Parameters ante- and post-partum

	Antepartum	Postpartum	
Parameter	Mean (SD)	Mean (SD)	P-value
			(two sided)
CO (L/min)	7.4	7.1	
SV (mL)	92	88	
Left ventricular Ejection Fraction (%)	63 (3)	62 (5)	0.68
Global Longitudinal Strain (%)	-21.5 (1.5)	-20.2 (2.0)	0.20
Left ventricular End Diastolic Volume (ml)	143 (41)	159 (45)	0.17
Left ventricular End Systolic Volume (ml)	53 (15)	60 (19)	0.14
Interventricular Septal Diameter (cm)	0.9 (0.2)	0.9 (0.2)	0.85
Left ventricular posterior wall diameter (cm)	1.0 (0.2)	0.9 (0.2)	0.53
E/E' Average (cm/sec)	8.2 (2.0)	7.4 (2.0)	0.58

351

22

References: 353 354 Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. Aug 21 1. 355 2010;376(9741):631-44. doi:10.1016/s0140-6736(10)60279-6 356 Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, 2. 357 eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens. May 358 2008;21(5):521-6. doi:10.1038/ajh.2008.20 359 Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of 3. 360 maternal death: a systematic review. Lancet. Apr 1 2006;367(9516):1066-1074. 361 doi:10.1016/s0140-6736(06)68397-9 362 ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet 4. 363 Gynecol. Jan 2019;133(1):1. doi:10.1097/aog.0000000000003018 364 5. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. Apr 2008;51(4):970-5. doi:10.1161/hypertensionaha.107.107607 365 366 Masini G, Foo LF, Tay J, et al. Preeclampsia has two phenotypes which require different 6. 367 treatment strategies. Am J Obstet Gynecol. Feb 2022;226(2s):S1006-s1018. 368 doi:10.1016/j.ajog.2020.10.052 Thilaganathan B, Kalafat E. Cardiovascular System in Preeclampsia and Beyond. 369 7. 370 Hypertension. Mar 2019;73(3):522-531. doi:10.1161/hypertensionaha.118.11191 371 Akkermans J, Diepeveen M, Ganzevoort W, van Montfrans GA, Westerhof BE, Wolf H. 8. 372 Continuous non-invasive blood pressure monitoring, a validation study of Nexfin in a pregnant 373 population. Hypertens Pregnancy. May 2009;28(2):230-42. doi:10.1080/10641950802601260 374 9. Doherty A, Carvalho JC, Drewlo S, et al. Altered hemodynamics and hyperuricemia 375 accompany an elevated sFlt-1/PIGF ratio before the onset of early severe preeclampsia. J 376 Obstet Gynaecol Can. Aug 2014;36(8):692-700. doi:10.1016/s1701-2163(15)30511-9 377 Doherty A, El-Khuffash A, Monteith C, et al. Comparison of bioreactance and 10. 378 echocardiographic non-invasive cardiac output monitoring and myocardial function assessment 379 in primagravida women. Br J Anaesth. Apr 1 2017;118(4):527-532. doi:10.1093/bja/aex045 380 11. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. Jan 381 2019;133(1):e26-e50. doi:10.1097/aog.000000000003020 382 12. Clearsite Finger Cuff Operator Manual. https://www.edwards.com/healthcare-383 professionals/products-services/predictive-monitoring/acumen-ig-384 cuff?utm source=google&utm medium=cpc&utm campaign=14737934628&utm content=14 2368364297&utm term=clearsight%20finger%20cuff&creative=641674311826&placement=& 385 matchtype=p&gclid=Cj0KCQiA5NSdBhDfARIsALzs2EBiUmCLmPQqmJE6KKPWo2XFWcp9zoS8BG 386 387 7E3TPYFMIzZRwBLvrBgfMaAk6dEALw wcB#disclaimer 388 13. Marik PE. Noninvasive cardiac output monitors: a state-of the-art review. J Cardiothorac 389 Vasc Anesth. Feb 2013;27(1):121-34. doi:10.1053/j.jvca.2012.03.022 390 Cornette J, Laker S, Jeffery B, et al. Validation of maternal cardiac output assessed by 14. 391 transthoracic echocardiography against pulmonary artery catheterization in severely ill 392 pregnant women: prospective comparative study and systematic review. Ultrasound Obstet 393 Gynecol. Jan 2017;49(1):25-31. doi:10.1002/uog.16015 394 15. Kusumoto F, Venet T, Schiller NB, Sebastian A, Foster E. Measurement of aortic blood 395 flow by Doppler echocardiography: temporal, technician, and reader variability in normal

- subjects and the application of generalizability theory in clinical research. J Am Soc *Echocardiogr*. Sep-Oct 1995;8(5 Pt 1):647-53. doi:10.1016/s0894-7317(05)80378-5
 Critchley LA, Critchley JA. A meta-analysis of studies using bias and precision statistics to
 compare cardiac output measurement techniques. J Clin Monit Comput. Feb 1999;15(2):85-91.
 doi:10.1023/a:1009982611386
 Cecconi M, Rhodes A, Poloniecki J, Della Rocca G, Grounds RM. Bench-to-bedside
- 402 review: the importance of the precision of the reference technique in method comparison
- 403 studies--with specific reference to the measurement of cardiac output. *Crit Care*.

404 2009;13(1):201. doi:10.1186/cc7129

- Belfort MA, Rokey R, Saade GR, Moise KJ, Jr. Rapid echocardiographic assessment of left
 and right heart hemodynamics in critically ill obstetric patients. *Am J Obstet Gynecol*. Oct
 1994;171(4):884-92. doi:10.1016/s0002-9378(94)70055-9
- 408 19. Eeftinck Schattenkerk DW, van Lieshout JJ, van den Meiracker AH, et al. Nexfin
- 409 noninvasive continuous blood pressure validated against Riva-Rocci/Korotkoff. Am J Hypertens.
- 410 Apr 2009;22(4):378-83. doi:10.1038/ajh.2008.368
- 411 20. Duclos G, Hili A, Resseguier N, et al. Clearsight[™] use for haemodynamic monitoring
- 412 during the third trimester of pregnancy a validation study. *Int J Obstet Anesth*. Nov
 413 2018;36:85-95. doi:10.1016/j.ijoa.2018.04.009
- 414 21. Vinayagam D, Patey O, Thilaganathan B, Khalil A. Cardiac output assessment in
- 415 pregnancy: comparison of two automated monitors with echocardiography. *Ultrasound Obstet*416 *Gynecol.* Jan 2017;49(1):32-38. doi:10.1002/uog.15915
- 417 22. Ouzounian JG, Elkayam U. Physiologic changes during normal pregnancy and delivery.
- 418 *Cardiol Clin*. Aug 2012;30(3):317-29. doi:10.1016/j.ccl.2012.05.004
- 419